433 related articles for article (PubMed ID: 16788079)
1. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
[TBL] [Abstract][Full Text] [Related]
2. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
3. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
4. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
5. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
7. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Harry RD; Zakzanis KK
Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
[TBL] [Abstract][Full Text] [Related]
8. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
9. Two galantamine titration regimens in patients switched from donepezil.
Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
11. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
[TBL] [Abstract][Full Text] [Related]
12. Anticholinesterase duration in the Australian veteran population.
Gadzhanova S; Roughead L; Mackson J
Aust N Z J Psychiatry; 2010 May; 44(5):469-74. PubMed ID: 20397790
[TBL] [Abstract][Full Text] [Related]
13. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M
Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
[TBL] [Abstract][Full Text] [Related]
14. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
16. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
17. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
Caffarra P; Vezzadini G; Copelli S; Dieci F; Messa G; Nonis E; Venneri A
Acta Biomed; 2007; 78(1):16-21. PubMed ID: 17687812
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase inhibitors in the treatment of dementia.
Ellis JM
J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
